A drug taken by millions, tested on almost nobody this old

Statins are among the most widely prescribed medications in the world, and decades of trial data back their use in people with existing heart disease or well-established risk factors. What's been missing, oddly, is solid evidence for a much simpler question: does starting a statin for the first time actually help a healthy person who's already 70 or older? Fewer than a quarter of participants across the major trials underpinning current statin guidelines were even that old. Results from the STAREE trial, presented at the European Society of Cardiology Congress in Munich and published simultaneously in the New England Journal of Medicine, finally close a meaningful chunk of that gap, and the answer they deliver is genuinely mixed.

Atorvastatin cut major cardiovascular events by 30% relative to placebo in healthy older adults with no history of heart disease, diabetes, or dementia. It did not, however, extend disability-free survival, the trial's other primary measure of success. Both findings matter, and they don't point in quite the same direction.

The trial that finally included this age group

STAREE, short for STAtin therapy for Reducing Events in the Elderly, enrolled 9,971 community-dwelling adults aged 70 or older across Australia, all free of clinical cardiovascular disease, diabetes, or dementia at the start. Participants were randomly assigned to either atorvastatin, starting at 20 mg daily and increasing to 40 mg after four weeks if tolerated, or a matching placebo, and were followed for a median of 5.9 years. Lead investigator Sophia Zoungas, of Monash University and the George Institute for Global Health, framed the trial's core contribution plainly: "STAREE is the first large-scale trial of a statin for primary prevention to show cardiovascular benefit in people aged 70 years and older." Given that an estimated 21,000 older Australians suffer a major cardiovascular event every year, according to figures Zoungas cited, a trial powered specifically to answer this age group's question carries real practical weight.

What the numbers actually showed

The primary cardiovascular endpoint, a composite of cardiovascular death, nonfatal heart attack, stroke, or coronary revascularization, occurred in 6.0% of the atorvastatin group compared with 8.3% of the placebo group, a 30% relative risk reduction that was highly statistically significant. That's a substantial effect size for a primary prevention trial in a population many clinicians had previously assumed was simply too old to benefit meaningfully from starting a new preventive medication.

The trial's second primary endpoint told a different story. Disability-free survival, defined as remaining alive without dementia or persistent physical disability, showed no meaningful difference between groups: 12.8% of the atorvastatin arm experienced the composite negative outcome compared with 13.6% on placebo, a gap well short of statistical significance. In plain terms, atorvastatin measurably reduced the chance of having a heart attack or stroke, but it didn't translate into people living more years free of disability or dementia overall, at least not within the roughly six-year window this trial measured.

Why fewer heart attacks didn't mean more healthy years

That disconnect is the detail worth sitting with. The study authors themselves flagged it directly: "A notable finding is that the lower incidence of major, nonfatal cardiovascular events with atorvastatin than with placebo did not result in a corresponding improvement in disability-free survival." There are a few plausible explanations, none of which the trial can fully settle on its own. Preventing a heart attack doesn't automatically prevent dementia or physical decline from other causes, which remain the dominant drivers of disability in this age group regardless of cardiovascular status. It's also possible the six-year follow-up window simply wasn't long enough to capture a benefit that would show up over a longer stretch, particularly for an outcome as slow-developing as dementia.

Safety data added useful context without changing the core trade-off. Musculoskeletal, hepatobiliary, and diabetes-related adverse events were more frequent in the atorvastatin group, the familiar side-effect profile statins carry in any population. But serious adverse events overall were rare and nearly identical between groups, 2.7% in each arm, according to the trial's safety reporting. Adherence also declined steadily over time, from 80.2% of atorvastatin-assigned participants still taking the drug at one year down to 55.6% by year five, a real-world reminder that even a well-tolerated preventive medication faces meaningful drop-off over a multi-year commitment.

What cardiologists are actually saying this means

The clinical reaction has settled into a fairly consistent, carefully hedged message: this is a genuine reason to reconsider blanket assumptions about age and statin eligibility, but not a reason to put every healthy 70-year-old on the drug automatically. François Mach, discussing the results, argued that "age alone should no longer be used as a reason to withhold statin therapy for primary prevention," while explicitly cautioning that "STAREE does not mean that every person 70 years or older should automatically receive statin treatment." Zoungas herself echoed that individualized framing, describing the decision as "a conversation that a person needs to have with their physician, weighing up the risks and benefits and understanding whether they will be able to tolerate a statin."

That's a meaningfully different message than a simple "statins work, start prescribing them more broadly." It's closer to: the evidence gap that justified withholding statins from healthy older adults purely on age has now narrowed considerably, but individual risk tolerance, expected years of benefit, and side-effect susceptibility still belong squarely in that conversation.

A trial still to come that could settle the bigger question

STAREE isn't the final word on this topic, and researchers are already looking ahead to a considerably larger study that could clarify the disability and dementia question this trial couldn't fully answer. The ongoing PREVENTABLE trial, discussed alongside STAREE's presentation, plans to enroll roughly 20,000 participants using the same 40 mg daily atorvastatin dose, giving it substantially more statistical power to detect effects on dementia and disability specifically than STAREE's smaller cohort could manage. Amgad Damluji, commenting on the results, noted there's reason for optimism that PREVENTABLE may eventually show statin therapy helps prevent dementia or disability in addition to cardiovascular events, a question STAREE raised without conclusively answering.

What this means for patients right now

For a healthy 70-something with no cardiovascular history weighing whether to start a statin, STAREE offers genuinely useful, if incomplete, guidance. The cardiovascular benefit is real and substantial, a 30% relative reduction in major events is not a marginal effect, and the safety profile in this trial looked broadly consistent with what's already known about statins in younger populations, without a spike in serious adverse events. What it doesn't offer is a guarantee that preventing a heart attack now translates into more years of independent, disability-free living later, since that outcome showed no measurable difference over the trial's follow-up period. For now, the honest clinical answer sits exactly where Zoungas and Mach both put it: not a blanket recommendation, but solid new evidence to bring into an individualized conversation between an older patient and their doctor, one that finally has real trial data behind it rather than extrapolation from younger populations.